EU Moves To RATIFY Novartis' Rydapt for AML

 
• By Kevin Grogan

Rydapt represents the first major development in targeted acute myeloid leukaemia treatment in more than 25 years as Novartis plots its commercial launch in Europe.

Approve
Novartis moves ahead of the competition with Rydapt approval • Source: Shutterstock

More from Anticancer

More from Therapy Areas